Actio Biosciences, Inc. Company Profile

Background

Actio Biosciences, Inc., founded in October 2021 and headquartered in San Diego, California, is a biotechnology company dedicated to developing therapeutics that target shared genetic pathways in both rare and common diseases. By leveraging advances in genetics and precision medicine, Actio aims to transform genetic insights into meaningful treatments, addressing unmet medical needs across diverse patient populations.

Key Strategic Focus

Actio's strategic focus centers on:

Precision Medicine Approach: Utilizing a proprietary human genetics platform to identify and modulate disease targets, starting with rare diseases to gain insights applicable to more prevalent conditions.

Rare Disease Target Atlas: A comprehensive database encompassing approximately 4,000 known Mendelian diseases, facilitating the identification of high-value therapeutic targets.

Lead Program: Development of ABS-0871, a small molecule targeting TRPV4 mutations, initially for Charcot-Marie-Tooth disease type 2C (CMT2C) and related bone diseases.

Financials and Funding

Actio Biosciences has secured significant funding to advance its research and development initiatives:

Series A Financing: In September 2023, the company completed a $55 million Series A financing round led by Canaan and DROIA Ventures, with participation from Deerfield Management, EcoR1, and Euclidean Capital.

Total Funding: As of 2024, Actio has raised a total of $63 million, including prior seed funding.

Pipeline Development

Actio's pipeline includes:

ABS-0871: A TRPV4 inhibitor targeting CMT2C and TRPV4-related bone diseases. Preclinical models have demonstrated significant improvements in motor function and mobility. The U.S. FDA granted orphan drug and rare pediatric disease designations for ABS-0871 in August 2024.

Additional Programs: Two other programs are under evaluation for genetic epilepsies and genetic skin conditions.

Technological Platform and Innovation

Actio's innovation is driven by:

Rare Disease Target Atlas: A proprietary database integrating extensive genetic information to identify and prioritize therapeutic targets.

Partnerships: Collaboration with The Jackson Laboratory's Rare Disease Translational Center to develop transgenic models for rare disease pathways, enhancing preclinical validation.

Leadership Team

Actio's leadership comprises experienced professionals:

David Goldstein, Ph.D.: Co-founder and CEO, a human geneticist with a focus on disease genetics and pharmacogenetics.

John McHutchison, AO, M.D.: Co-founder and Board Member, with extensive experience in clinical development across multiple therapeutic areas.

Cayce Denton: Chief Financial Officer, appointed in January 2025, bringing over two decades of experience in finance and strategy within the biotech industry.

Dimitrios Arkilo, M.D.: Chief Medical Officer, a board-certified child neurologist with expertise in pediatric epilepsy.

David Breckenridge, Ph.D.: Chief Scientific Officer, leading scientific research and development efforts.

Leadership Changes

In January 2025, Actio appointed Cayce Denton as Chief Financial Officer, enhancing the company's financial strategy and operations.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector focusing on precision medicine for rare and common diseases is rapidly evolving, with increasing investments in genetic research and targeted therapies.

Competitor Analysis

Key competitors include:

Akouos: Specializes in gene therapies for hearing disorders.

Envigo: Provides research models and services.

Klox Technologies: Focuses on regenerative medicine.

TES Pharma: Engages in delivering preclinical candidates.

Strategic Collaborations and Partnerships

Actio has established significant collaborations to bolster its research capabilities:

The Jackson Laboratory: Partnership to develop and implement transgenic models of rare disease pathways, enhancing preclinical research.

Operational Insights

Actio's strategic approach of targeting rare diseases to gain insights applicable to common conditions positions it uniquely in the biotechnology landscape. This methodology aims to de-risk drug development and expand therapeutic applications.